Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics finalises plans for cosmetic study; updates on manufacturing scale-up

With 120 women taking part, the study is double the original size
woman at mirror inspecting skin
Scientists will assess for visual dryness, skin hydration and skin barrier function

SkinBioTherapeutics PLC (LON:SBTX) said it has finalised plans for its human study of the cosmetic application of its SkinBiotix technology while it announced progress with the manufacturing scale-up of the product.

The former first: the assessment of 120 female volunteers with dry skin will take place in the third quarter with testing being carried out by clinical research firm Alba Science.

READ: 'Huge milestone' for SkinBioTherapeutics with cream formulation success

Scientists will assess for visual dryness, skin hydration and skin barrier function with swab samples to be taken at the beginning and end of the study to examine the effects of the technology on the skin microbiome.

By using the cream, it is hoped hydration of the skin will be improved; the barrier function will be stronger (shown by a decrease in water loss across the skin barrier); and it will be confirmed that the technology is safe for the skin microbiome.

Study doubles in size 

"We are determined to make the study as impactful as possible, which is why we have doubled its size,” said chief executive, Dr Cath O'Neill.

“The cost impact is marginal, but the increase in the strength of the potential data and hence, to future partnering discussions, could be significant. Scaling up the manufacturing process is a key step in our development, and we are also moving this forward very well."

Turning to the manufacturing process, SkinBioTherapeutics a new production method that is scalable has been successfully trialled.

The results indicated no detrimental impact upon the active properties of the SkinBiotix technology.

The company said further work is required to optimise the process to achieve manufacturing on a commercial scale but the progress to date is “encouraging”.

In the same announcement, SkinBioTherapeutics said a patent covering the use for specific probiotic bacteria and lysates in skin health has been granted in New Zealand and Russia.

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month
scientist in lab
September 11 2018
The phase 1b trial of Silence’s lead candidate, SLN124, a treatment for a rare blood disorder, is scheduled to begin in the second half of 2019

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use